RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.The ANDA filing can only be a 505(b)(2) filing, which is the equivalent of an NDA. That's how it's presented in the investor presentation. And Pidduck talked about the application and referred to it as an NDA. The active ingredients of Epidiolex cannot be patented. So if a new therapy is discovered, Epidiolex can be marketed as a new drug without infringing the patents. The new drug may only not be used to treat epilepsy, as this therapy is protected by patents.